News
Google News
More headlines & perspectives

Incyte to pay $1.25 billion upfront for Vega Therapeutics

Top news

Business Wire

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Reuters

Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff

By Siddhi Mahatole
WSJ

Incyte to Buy Vega Therapeutics For Up to $2 Billion

By Colin Kellaher
Endpoints News

Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal

By Kyle Lahucik

All coverage

Fierce Biotech

Incyte inks $2B deal to add Star biz to late-phase constellation

Financial Times

Incyte strikes up to $2bn deal for blood disorder biotech

By Oliver Barnes
The Business Journals

Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion

By Ron Leuty
TradingView

INCY: Acquisition adds a transformative VWD therapy, boosting growth and market expansion

geneonline.com

Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion

BioWorld News

Incyte nabs potential VWD game-changer in Vega deal; J&J buys Firefly

By Jennifer Boggs
MedCity News

Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug

By Frank Vinluan
Pharmaceutical Executive

Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio

By Nicholas I Jacobus
The Pharma Letter

BRIEF—Incyte eyeing acquisition of Star Therapeutics

GuruFocus

Incyte Corporation (INCY) Announces Acquisition of Vega Therapeu

Investing.com India

Oppenheimer raises Incyte stock price target on Vega acquisition By Investing.com

Pluang

Incyte to acquire Vega Therapeutics for $2B, expanding into bleeding disorder treatments.

marketscreener.com

Transcript : Incyte Corporation, Vega Therapeutics, Inc. - M&A Call

Pharmaceutical Technology

Incyte bolsters haematology portfolio in $2bn Vega buyout

By Annabel Kartal-allen
Law360

Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B

By Al Barbarino
BioSpace

Incyte’s stars align as new CEO strikes $2B Vega takeover for blood disorder asset

By Annalee Armstrong
Seeking Alpha

Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT (INCY:NASDAQ)

By Rob Williams
Yahoo Finance

Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary

StreetInsider

Incyte (INCY) PT Raised to $107 at Oppenheimer

BioPharma Dive

Incyte to buy blood disorder drug in possibly $2B deal

By Jacob Bell
pharmaphorum

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Axios

Incyte makes $2B bleeding disorder play

By Natalie Breymeyer
BioXconomy

Incyte snaps up Vega Therapeutics in $2bn hematology play

By Millie Nelson
FirstWord Pharma

Incyte makes Vega deal official, paying $1.25B upfront for bleeding disorder biotech

Contract Pharma

Incyte Agrees to Acquire Vega Therapeutics for $1.25B

whbl.com

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

Pulse 2.0

Incyte To Acquire Vega Therapeutics For Up To $2 Billion To Expand Hematology Portfolio Into Bleeding Disorders

By Amit Chowdhry
grafa.com

Incyte acquires Vega Therapeutics in $1.25 billion deal

By Jon Cuthbert
The Joplin Globe

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

citybiz

Incyte to Acquire Vega Therapeutics in Up to $2 Billion Hematology Expansion

MSN

Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary

TipRanks

Incyte to Acquire Vega Therapeutics in $2B Deal

Delaware Business Now

Incyte to buy bleeding disorder drug candidate in deal valued at up to $2 billion

TradingView

INCY: Acquisition of a phase III asset in von Willebrand disease targets blockbuster growth post-2029

Endpoints News

Incyte's Meury, now a buyer, sees $2B Vega deal as a step in blood treatments beyond Jakafi

By Kyle Lahucik
TradingView

INCY: Acquisition adds a phase III asset with $1B+ sales potential and FDA Breakthrough status

The Pharma Letter

Incyte to acquire Star subsidiary Vega Therapeutics

Investing.com Canada

Oppenheimer raises Incyte stock price target on Vega acquisition By Investing.com

marketscreener.com

Incyte Corporation entered into a definitive agreement to acquire to acquire Vega Therapeutics, Inc. from Star Therapeutics, Inc. for $2 billion.

The Business Journals

Incyte to acquire Vega Therapeutics in deal valued at up to $2B

By Jonathan Diamond
Axios

Incyte makes $2B bleeding disorder play

By Natalie Breymeyer
WSAU

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

WNWN-FM

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

Yahoo Finance

Incyte to buy blood disorder drug in possibly $2B deal

By Jacob Bell
GuruFocus

Incyte (INCY) to Acquire Vega Therapeutics for $1.25B

Delaware Business Now

Incyte to buy company in late stages of development of bleeding control drug

TradingView

Incyte to acquire Vega Therapeutics for $1.25B, up to $2.0B with milestones; VGA039 Phase 3 asset

FirstWord Pharma

Incyte eyeing $2B deal for Star to grow haematology pipeline: report

By Anna Bratulic
GuruFocus

Incyte Corp. (INCY) Nears $2 Billion Acquisition of Star Therape

Search
Clear search
Close search
Google apps
Main menu